national
FDA Approves Diagnostic Blood Test for Alzheimer's Disease Developed by Roche and Eli Lilly
Just the facts
The U.S. Food and Drug Administration granted official regulatory approval for an Alzheimer's disease diagnostic blood test developed through a joint initiative between pharmaceutical companies Roche and Eli Lilly. The diagnostic test measures specific blood biomarkers associated with amyloid plaque accumulation in the human brain, offering a non-invasive alternative to traditional lumbar punctures and specialized brain scans. Healthcare providers can utilize the blood test to evaluate adult patients exhibiting cognitive decline and memory impairment symptoms. Regulatory clearance enables commercial distribution and clinical adoption across medical facilities within the United States.
Why this is news
The U.S. Food and Drug Administration approved a new diagnostic blood test co-developed by healthcare firms Roche and Eli Lilly to assist in detecting Alzheimer's disease.
Sources
This summary is compiled strictly from the original reporting below.